Why is Unichem Laboratories Ltd falling/rising?

Recent Price Movement and Market Performance

Unichem Laboratories hit a fresh 52-week low of ₹430.5 on 30 December, marking a continuation of a downward trend that has persisted over the past five trading sessions. During this period, the stock has lost 4.39% of its value, underperforming its sector by 2.53% on the day. The intraday low of ₹430.5 represents a 2.76% decline from the previous close, signalling sustained selling pressure. Furthermore, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical outlook.

Investor participation has also waned, with delivery volumes on 29 December falling by 31.85% compared to the five-day average. This decline in trading activity suggests reduced confidence among shareholders and a lack of fresh buying interest, which exacerbates downward price momentum.

Financial Performance and Valuation Metrics

Despite the recent price weakness, Unichem Laboratories exhibits some positive financial attributes. The company’s operating profit has grown at an annualised rate of 37.55%, reflecting healthy long-term operational growth. Additionally, the return on capital employed (ROCE) stands at 4.9%, and the enterprise value to capital employed ratio is a modest 1.2, suggesting the stock is trading at a discount relative to its peers’ historical valuations. Notably, profits have surged by 419.9% over the past year, even as the stock price declined by 39.21%, resulting in a low PEG ratio of 0.1, which could indicate undervaluation from a growth perspective.

However, these positives are overshadowed by several critical concerns that have weighed heavily on investor sentiment and share price performance.

Debt Burden and Profitability Challenges

One of the primary reasons for the stock’s decline is the company’s limited ability to service its debt. Unichem Laboratories carries a high Debt to EBITDA ratio of 4.87 times, signalling significant leverage and potential financial strain. The debt-equity ratio at the half-year mark is 0.21 times, the highest recorded, while interest expenses for the quarter have risen sharply by 25.99% to ₹8.24 crores. This increase in interest costs further pressures profitability and cash flows.

Moreover, the company’s return on equity (ROE) averages a mere 1.44%, indicating low profitability relative to shareholders’ funds. Net sales growth has been modest at an annual rate of 12.60% over the last five years, which is insufficient to inspire confidence in sustained top-line expansion. The flat results reported in September 2025, combined with non-operating income constituting 44.20% of profit before tax, raise questions about the quality and sustainability of earnings.

These financial weaknesses have contributed to the stock’s underperformance relative to broader market indices. Over the past year, Unichem Laboratories has delivered a negative return of 39.21%, while the Sensex has gained 8.21%. Similarly, over three and five years, the stock’s returns lag behind the benchmark, underscoring persistent challenges in generating shareholder value.

Conclusion: Why the Stock is Falling

In summary, Unichem Laboratories Ltd’s share price decline on 30 December and over recent weeks is primarily driven by concerns over its high leverage and weak debt servicing capacity, coupled with subdued sales growth and low profitability metrics. Despite attractive valuation multiples and impressive profit growth, the market remains cautious due to the company’s flat recent results, rising interest expenses, and underperformance relative to benchmarks. The stock’s technical indicators and falling investor participation further reinforce the bearish sentiment.

Investors should weigh these factors carefully, considering both the company’s long-term growth potential and the immediate financial risks before making investment decisions.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →